Overview

A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2019-05-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the effect of rovalpituzumab tesirine in the frontline treatment of small cell lung cancer (SCLC).
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie
Stemcentrx
Treatments:
Cisplatin
Etoposide
Etoposide phosphate